NASDAQ: CORV, TSX: CORV
Article Awarded the 10th Luis
Jiménez Murillo Prize, Which Will Be Presented During
Ceremony at SEMES 2018 in Toledo, Spain
VANCOUVER, June 6, 2018
/CNW/ - Correvio Pharma Corp. (NASDAQ:CORV / TSX:CORV), a
revenue-generating, specialty pharmaceutical company focused on
commercializing hospital drugs, today announced that the
Brinavess® study, titled "Vernakalant in hospital
emergency practice: safety and effectiveness," published by José
Carbajosa Dalmau (Alicante, Spain), was awarded first prize for the best
work published during the year 2017 in the medical journal
EMERGENCIAS, a prestigious, emergency room focused medical journal
in Spain. The award will be presented to Dr. Carbajosa Dalmau
at a ceremony at the Spanish Society of Emergency Medicine
(SEMES) 30th National Congress 2018, being held June 6-8, 2018 in Toledo, Spain.
"We are honored to see that this Brinavess study was selected to
receive the award from the SEMES and believe it underscores
Brinavess' importance for patients where pharmacologic
cardioversion is appropriate," said Kiran Bhirangi, M.D.,
Correvio's Vice President, Clinical Development and Medical
Affairs. "Brinavess is currently marketed in 33 countries across
the globe and has repeatedly demonstrated its ability to rapidly
induce cardioversion in real-world clinical practice."
This prospective multicenter study (Carbajosa Dalmau, et
al. 2017) investigated the safety and effectiveness of
Brinavess (vernakalant hydrochloride, IV) for the rapid conversion
of recent onset atrial fibrillation (AF), in routine hospital
emergency department care in Spain, and assessed factors associated with a
more effective response. The study evaluated 165 cases where
patients were administered Brinavess for pharmacologic
cardioversion of AF between September
2014 and March 2016 in 5
hospitals in Valencia,
Spain. The data demonstrated that cardioversion with
Brinavess was effective in 77.6% (95% CI, 71.1%–84%) of cases.
The median time to conversion was 8 minutes (range 6-12
minutes) after the first dose and 34 minutes (range 22-62 minutes)
after a second dose. There was a statistically significant
association between AF duration of less than 12 hours and greater
effectiveness of Brinavess (83.6% versus 59.5%; adjusted odds
ratio, 2.76; 95% CI, 1.12 – 6.80; p=0.03). Adverse events
were reported for 30 patients (18%). None of the events had
clinically important consequences, and only 2 cases (1.2%) required
suspension of treatment.
A copy of this previously published Brinavess study can be
accessed online here.
About Atrial Fibrillation
Atrial Fibrillation (also known as AFib or AF) is a
supraventricular tachyarrhythmia with uncoordinated atrial
activation resulting in ineffective atrial contraction and if left
untreated, structural and/or electrophysiological atrial tissue
abnormalities.1 AF is a common cardiac rhythm
disturbance that increases in prevalence with advancing
age.1 According to the American Heart Association,
estimates of the prevalence of AF in the U.S. ranged from 2.7
million to 6.1 million in 2010, and is expected to rise to between
5.6 million to 12 million in 2030.2 There are two
strategies to manage AF, namely, rhythm- or rate-control. A
rhythm-control strategy may be used in patients who are severely
compromised, remain symptomatic despite adequate rate control, when
adequate rate control is difficult to achieve, when long term
rhythm control therapy is preferred, younger patient age, presence
of tachycardia-mediated cardiomyopathy, and first episode of
AF.1,3 Early intervention with a rhythm-control strategy
to prevent progression of AF may be particularly beneficial to the
AF patient.1
About BRINAVESS®
Brinavess® (vernakalant HCl, IV) is an antiarrhythmic
drug that acts preferentially in the atria by prolonging atrial
refractoriness and slowing impulse conduction in a rate-dependent
fashion. Brinavess is approved for marketing in Europe, Canada and several other countries worldwide.
In Europe, it is approved for the
rapid conversion of recent onset atrial fibrillation to sinus
rhythm in adults: 1) for non-surgery patients: atrial fibrillation
< 7 days duration; and 2) for post-cardiac surgery patients:
atrial fibrillation < 3 days duration. Vernakalant IV is not
approved for use in the United
States.
References
- January CT et al. 2014 AHA/ACC /HRS guideline for the
management of patients with atrial fibrillation. J AM Coll Cardiol.
2014;34:e1-e76.
- Mozaffarian D et al. Heart Disease and Stroke Statistics-2016
Update: A Report From the American Heart Association. Circulation.
2016 Jan 26;133(4):e38-60.
- Kirchhof P et al. 2016 ESC Guidelines for the management of
atrial fibrillation developed in collaboration with EACTS European
Heart Journal (2016) 37, 2893–2962.
- Carbajosa Dalmau J, et al. Seguridad y eficacia de vernakalant
en la práctica clínica de los servicios de urgencias [Vernakalant
in hospital emergency practice: safety and effectiveness].
Emergencias 2017;29:397-402
About Correvio Pharma Corp.
Correvio Pharma Corp. is a revenue-generating, specialty
pharmaceutical company focused on providing innovative,
high-quality brands that meet the needs of acute care physicians
and patients. With a commercial presence and distribution network
covering over 60 countries worldwide, Correvio develops, acquires
and commercializes brands for the in-hospital, acute care market
segment. The Company's portfolio of approved and marketed brands
includes: Xydalba™ (dalbavancin hydrochloride), for the
treatment of acute bacterial skin and skin structure infections
(ABSSSI); Zevtera®/Mabelio® (ceftobiprole
medocaril sodium), a cephalosporin antibiotic for the treatment of
community- and hospital-acquired pneumonia (CAP, HAP);
Brinavess® (vernakalant IV) for the rapid conversion of
recent onset atrial fibrillation to sinus rhythm;
Aggrastat® (tirofiban hydrochloride) for the reduction
of thrombotic cardiovascular events in patients with acute coronary
syndrome, and Esmocard® and Esmocard Lyo®
(esmolol hydrochloride), a short-acting betablocker used to control
rapid heart rate in a number of cardiovascular indications.
Correvio's pipeline of product candidates includes
Trevyent®, a drug device combination that is designed to
deliver treprostinil, the world's leading treatment for pulmonary
arterial hypertension.
Correvio is traded on the NASDAQ Capital Market (CORV) and the
Toronto Stock Exchange (CORV). For more information, please visit
our web site www.correvio.com.
Forward-Looking Statement Disclaimer
Certain statements in this news release contain forward-looking
statements within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995 or forward-looking information under
applicable Canadian securities legislation ("forward-looking
statements") that may not be based on historical fact, including
without limitation statements containing the words "believe",
"may", "plan", "will", "estimate", "continue", "anticipate",
"intend", "expect" and similar expressions. Such forward-looking
statements involve known and unknown risks, uncertainties and other
factors that may cause the actual results, events or developments
to be materially different from any future results, events or
developments expressed or implied by such forward-looking
statements. A discussion of the risks and uncertainties facing
Correvio are discussed in the most recent annual and quarterly
reports of our former parent company Cardiome Pharma Corp., and
detailed from time to time in our other filings with the Securities
and Exchange Commission ("SEC") available at www.sec.gov and the
Canadian securities regulatory authorities at www.sedar.com. All of
the risks and certainties disclosed in these filings are hereby
incorporated by reference in their entirety. While Correvio makes
these forward-looking statements in good faith, given these risks,
uncertainties and factors, you are cautioned not to place undue
reliance on any forward-looking statements made in this press
release. All forward-looking statements made herein are based on
our current expectations and we undertake no obligation to revise
or update such forward-looking statements to reflect subsequent
events or circumstances, except as required by law.
Correvio® and the Correvio Logo are the proprietary
trademarks of Correvio Pharma Corp.
Aggrastat® and Brinavess® are trademarks
owned by Correvio and its affiliates worldwide.
Xydalba™ is a trademark of Allergan Pharmaceuticals International
Limited, and used under license.
Zevtera® and Mabelio® are trademarks owned by
Basilea Pharmaceutica International Ltd., and used under
license.
Esmocard® and Esmocard Lyo® are trademarks
owned by Orpha-Devel Handels und Vertriebs GmbH, and used under
license.
Trevyent® is a trademark of SteadyMed and used under
license.
All other trademarks are the property of their respective
owners.
View original
content:http://www.prnewswire.com/news-releases/brinavess-data-receives-top-award-for-best-article-published-in-the-spanish-medical-journal-emergencias-300660446.html
SOURCE Correvio Pharma Corp